Two Indian nationals are facing charges relating to the sale of counterfeit versions of Novo's diabetes treatment Ozempic to distributors in the US.

Former Republican lawmaker Eric Cantor has been named as the new CEO of US pharma group PhRMA, replacing long-serving Stephen Ubl.

uniQure's latest data drop for its gene therapy for Huntington's disease, under review in the US and UK, has spooked investors.

Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.

Gilead's Hepcludex was the first drug to be cleared in the US for hepatitis D in May, but a potential rival from Mirum Pharma is already looming.

AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.

Sweden's Egetis has won approval in the US for the first-ever treatment for people living with ultra-rare genetic disease MCT8 deficiency.

MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.

Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.

A new study suggests long-read 'nanopore' sequencing could transform the diagnosis of inherited diseases and unlock new insights for drug discovery.

Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.

Trump's FDA nominee Heidi Overton was quizzed on a range of issues at her Senate hearing, including vaccines, the abortion pill, and agency reforms.

MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.

The infiltration of Australia's Medicare by an AI agent raises serious questions about patient privacy and the security of confidential pharma data.

Kyverna has data with miv-cel in stiff person syndrome that shows durable efficacy and safety and seems to sidestep issues flagged with other CAR-Ts.

Eli Lilly continues a busy period of deal-making with a five-project partnership with InnoCare that includes $100m in upfront and near-term payments.

FDA expert advisors voted in favour of Grail's Galleri blood test for detecting multiple cancers, but some expressed misgivings about its efficacy.

AI-powered drug discovery companies Enveda and Basecamp have completed impressive funding rounds, worth $311m and $140m, respectively.

Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.

The NIHR has revealed the first £45m in funding for projects that can bridge the translation gap in healthcare, focusing initially on community care.

UK Prime Minister Andy Burnham, who lost his father to Alzheimer's last week, has been urged to implement a "cancer-style" reform of dementia care.

In the space of a day, Iambic has filed an IPO, released the latest version of its AI platform, and signed a multi-year alliance with AbbVie.

CSL Seqirus' recently approved trivalent, cell-based influenza vaccine Aujemflu will be part of the UK's 2027/28 immunisation campaign.

Beacon is preparing to file for approval of its gene therapy for X-linked retinitis pigmentosa, after reporting encouraging phase 3 data.

Telix Pharma has reached a deal to acquire ITM, extending a wave of consolidation in the radiopharma category over the last couple of years.

Newsletters and Deep Dive digital magazine

Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.